The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.

about

The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.

Item

http://www.wikidata.org/entity/Q48194119

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The benefit of combination the ...... d duration in Crohn's disease.

@en

The benefit of combination the ...... d duration in Crohn's disease.

@nl

type

Item

label

The benefit of combination the ...... d duration in Crohn's disease.

@en

The benefit of combination the ...... d duration in Crohn's disease.

@nl

prefLabel

The benefit of combination the ...... d duration in Crohn's disease.

@en

The benefit of combination the ...... d duration in Crohn's disease.

@nl

P1476

The benefit of combination the ...... d duration in Crohn's disease.

@en

P2093

L Raffals

http://www.w3.org/2001/XMLSchema#string

M D Long

http://www.w3.org/2001/XMLSchema#string

R S Sandler

http://www.w3.org/2001/XMLSchema#string

P2860

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Inflammatory bowel disease

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

Epidemiology and natural history of inflammatory bowel diseases

Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States.

Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease

P304

162-168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/APT.14125

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Atsushi Sakuraba

Edward L Barnes

Ashwin N Ananthakrishnan

Joel Pekow

P577

2017-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28470787

http://www.w3.org/2001/XMLSchema#string

P932

5484085

http://www.w3.org/2001/XMLSchema#string